Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCell Pharma ABFRA:65G -5.84%42 PB Ratio is 1.73 as of Jul. 27, 2026, which is 44% below its 10-year median of 3.07. GuruFocus rates FRA:65G with a GF Score™ of 42/100 and a GF Value™ of €0.06 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,230 Biotechnology companies, NextCell Pharma AB ranks better than 58.7% on this metric.
The historical rank and industry rank for NextCell Pharma AB's PB Ratio or its related term are showing as below:
FRA:65G'
s PB Ratio Range Over the Past 10 Years
Min: 0.77 Med: 3.07 Max: 28.45
Current: 2.22
During the past 11 years, NextCell Pharma AB's highest PB Ratio was 28.45. The lowest was 0.77. And the median was 3.07.
FRA:65G's PB Ratio is ranked better than 58.7% of 1230
companies
in the Biotechnology industry
Industry Median: 2.785
vs FRA:65G: 2.22
During the past 12 months, NextCell Pharma AB's average Book Value Per Share Growth Rate was -44.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -39.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -15.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 7.80% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of NextCell Pharma AB was 106.60% per year. The lowest was -39.20% per year. And the median was 2.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
NextCell Pharma AB PB Ratio Related Terms
NextCell Pharma AB PB Ratio Historical Data
* Premium members only.
The historical data trend for NextCell Pharma AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NextCell Pharma AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCell Pharma AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where NextCell Pharma AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
NextCell Pharma AB (FRA:65G) has a PB Ratio of 1.73 as of Jul. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NextCell Pharma AB and its competitors. This is 44% below median its historical median of 3.07. Over the past decade, NextCell Pharma AB's PB Ratio has ranged from 0.77 to 28.45. According to the industry distribution chart, NextCell Pharma AB ranks #508 out of 1230 companies in the Biotechnology industry, placing it in the top 41.3%.
Is NextCell Pharma AB's PB Ratio too high?
NextCell Pharma AB's current PB Ratio of 1.73 is 44% below median its 10-year median of 3.07. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 28.45. The Biotechnology industry median PB Ratio is 2.79. NextCell Pharma AB's value of 1.73 is 37.9% below this industry median. Based on the distribution chart, NextCell Pharma AB ranks #508 out of 1230 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NextCell Pharma AB ranks #508 out of 1230 companies for PB Ratio. This puts NextCell Pharma AB in the upper half of its industry. The industry median PB Ratio is 2.79. NextCell Pharma AB's value of 1.73 is 37.9% below this benchmark. Historically, NextCell Pharma AB's own PB Ratio has ranged from 0.77 to 28.45 over the past decade. While the company's 10-year median is 3.07 vs. the industry median of 2.79, NextCell Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NextCell Pharma AB's current PB Ratio of 1.73 is 37.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NextCell Pharma AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NextCell Pharma AB's current PB Ratio is 1.73, which is 44% below median its own 10-year median of 3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.07 — trading 21% above its estimated fair value. The current PB Ratio is 1.73, which is 44% below median its 10-year median of 3.07 and 37.9% below the Biotechnology industry median of 2.79. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current PB Ratio is 1.73 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?
Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued.
The current stock price of €0.07 is trading 21% above its estimated GF Value™ of €0.06.
GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.
Key valuation signals for FRA:65G:
PB Ratio: 1.73 (44% below median its 10-year median of 3.07)
GF Value™: €0.06 vs. price of €0.07 (21% above fair value)
Industry Position: 37.9% below the Biotechnology median (#508 of 1230)
No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score
Get the complete analysis for FRA:65G
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:65G has been successfully added to your 
